Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum92263Research ArticleFormoterol – izvestnyy preparat i novoe sredstvo dostavkiKnyazheskayaN. P-15102006810767928122021Copyright © 2006, Consilium Medicum2006бронхиальная астмахроническая обструктивная болезнь легкихформотерол[Глобальная стратегия лечения и профилактики бронхиальной астмы. Под редакцией академика РАМН А.Г.Чучалина М.: Атмосфера, 2002.][Калманова Е.Н., Айсанов З.Р. Форадил и его место в терапии бронхиальной астмы. Пульмонология. 2001; 1: 65–72.][Хронические обструктивные болезни легких. Федеральная программа. М., 1999.][Anderson G.P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of highly potent and selective agonist bronchodilatator. Life Sci. 1993.][Barnes P.J. Effects of b2-agonists and steroids on b2-adrenoreceptor. Eur Respir Rev 1998; 8 (55): 210–5.][Barnes P.J. Clinical outcome of adding long - acting b2-agonists to inhaled corticosteroids. Respir Med 2001; 95 (Suppl. B): S12–6.][Bousquet J, Huchon G, Leclerc V et al. A randomized, double - blind, double - dummy, single - dose, efficacy croover trial comparing formoterol-HFA (pMDI) versus formoterol DPI (Aerolaizer) and placebo (pMDI orAerolaizer) in astmatic patients. Respiration 2005; suppl. 1: 6–12.][Bousquet J, Cantini L. Clinical studes in astmatics with a new non - extra fine HFA formulation of beclametasone dipropionate (BDP Modulite). Respir Med 2002; 96: S17–27.][Vervaet C, Byron P.R. Drug - surfactant - propellant interactions in HFA-formulations. Int J Pharm 1999; 186: 13–30.][Chint T. Changes in metered dose inhaler propellants/Rev Mal Respir 2000; 17: 15–20.][Greening A.P, Ind P.W, Northfield M, Shaw G. Added salmeterol versus higher - dose corticosteroids in asthma patients with symptoms on existing inhaled corticosteroids: Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219–24.][Dahl R, Greefhost L.A.R.M, Nowak D et al. Inhaled formoterol dry in cronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778–84.][Mak J.C.W, Nishikawa M, Shirasaki H et al. Protective effects of a glucocorticoid on downregulation of pulmonary b2-adrenergic receptors in vivo. J Clin Invest 1995; 96: 99–106.][Nials A.T, Ball D.I, Butchers P.R et al. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur J Pharmacol 1994; 251: 127–35.][O'Connor B.J, Alkinan S.L, Barnes P.J. Tolerance to the non - bronchodilatator effects of inhaled b2-agonists in asthma. N Engl J Med 1992;][Palmquist M et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999;][Politiek M.J, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine - induced severe bronchoconstriction. Eur Respir 1999;][Tattersfield A.E, Lofdahl C-G, Postma D.S et al. Comparison of formoterol and terbutaline for as - needed treatment of asthma: a randomised controlled trial. Lancet 2001; 357: 257–61.][van Noord J.A, Smeets J.J, Raaijmakers J.A et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996; 9: 1684–8.]